Evidence map›Paper›PMID 33813822›Full record

ArticleBiomacromolecules2021

Pluronic Micelle-Mediated Tissue Factor Silencing Enhances Hemocompatibility, Stemness, Differentiation Potential, and Paracrine Signaling of Mesenchymal Stem Cells.

Vignesh K Rangasami, Ganesh Nawale, Kenta Asawa, Sandeep Kadekar, Sumanta Samanta, Bo Nilsson, Kristina N Ekdahl, Susanna Miettinen, Jöns Hilborn, Yuji Teramura and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Biomacromolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Tailoring composite hydrogel performanceBiomaterials science · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Vignesh K RangasamiBioengineering and Nanomedicine Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere 33720, Finland.
Ganesh NawaleTranslational Chemical Biology Laboratory, Department of Chemistry, Ångström Laboratory, Uppsala University, Uppsala 751 21, Sweden.ORCID 0000-0002-7256-0758
Kenta AsawaDepartment of Bioengineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Sandeep KadekarTranslational Chemical Biology Laboratory, Department of Chemistry, Ångström Laboratory, Uppsala University, Uppsala 751 21, Sweden.
Sumanta SamantaBioengineering and Nanomedicine Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere 33720, Finland.
Bo NilssonDepartment of Immunology, Genetics, and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala SE-75105, Sweden.
Kristina N EkdahlDepartment of Immunology, Genetics, and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala SE-75105, Sweden.
Susanna MiettinenAdult Stem Cells Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere 33014, Finland.
Jöns HilbornPolymer Chemistry, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala 751 21, Sweden.
Yuji TeramuraDepartment of Bioengineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.ORCID 0000-0002-0709-1000
Oommen P VargheseDepartment of Bioengineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.ORCID 0000-0001-8872-9928
Oommen P OommenBioengineering and Nanomedicine Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere 33720, Finland.ORCID 0000-0003-2768-0133
Uppsala University · SETampere University · FIThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) evoke great excitement for treating different human diseases due to their ability to home inflamed tissues, suppress inflammation, and promote tissue regeneration. Despite great promises, clinical trial results are disappointing as allotransplantation of MSCs trigger thrombotic activity and are damaged by the complement system, compromising their survival and function. To overcome this, a new strategy is presented by the silencing of tissue factor (TF), a transmembrane protein that mediates procoagulant activity. Novel Pluronic-based micelles are designed with the pendant pyridyl disulfide group, which are used to conjugate TF-targeting siRNA by the thiol-exchange reaction. This nanocarrier design effectively delivered the payload to MSCs resulting in ∼72% TF knockdown (KD) without significant cytotoxicity. Hematological evaluation of MSCs and TF-KD MSCs in an ex vivo human whole blood model revealed a significant reduction in an instant-blood-mediated-inflammatory reaction as evidenced by reduced platelet aggregation (93% of free platelets in the TF-KD group, compared to 22% in untreated bone marrow-derived MSCs) and thrombin-antithrombin complex formation. Effective TF silencing induced higher MSC differentiation in osteogenic and adipogenic media and showed stronger paracrine suppression of proinflammatory cytokines in macrophages and higher stimulation in the presence of endotoxins. Thus, TF silencing can produce functional cells with higher fidelity, efficacy, and functions.

Indexed as

Mesenchymal Stem CellsCell DifferentiationCells, CulturedHumansMicellesParacrine CommunicationPoloxamerThromboplastinMicellesPoloxamerThromboplastin

Identifiers

PMID33813822
PMCPMC8154246
OpenAlexW3143658330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.